Literature DB >> 8712295

Alpha 1-antitrypsin expression in human thyroid papillary carcinoma.

M T Poblete1, F Nualart, M del Pozo, J A Perez, C D Figueroa.   

Abstract

Alpha 1-antitrypsin is a plasma serine protease inhibitor originally used as a marker for tumors of histiocytic origin. Our casual finding of immunoreactive alpha 1-antitrypsin in one case of thyroid papillary carcinoma led us to investigate its presence in 10 thyroid papillary carcinomas by applying immunocytochemical and immunochemical techniques to tissue sections and Western blots of tissue homogenates prepared from neoplastic tissue and from uninvolved normal areas in the vicinity of each tumor. The immunocytochemical study was performed in both thyroid tissue and metastatic regional lymph nodes. This analysis revealed immunoreactivity for alpha 1-antitrypsin in nine of the 10 cases studied. Immunoreactivity was intense in some of the cells forming the papillar and follicular structures. These cells were intermingled with completely unstained tumoral cells. In contrast to neoplastic tissue, the normal thyroid tissue present in the vicinity of each tumor showed no staining for alpha 1-antitrypsin. The electrophoretic analysis performed on homogenates prepared from both tumoral and normal thyroid tissue revealed a drastic reduction in the band corresponding to thyroglobulin in the tumoral tissue compared with normal thyroid extracts, where it represented the major protein. Western blotting and immunoprinting with a polyclonal alpha 1-antitrypsin antibody confirmed the results obtained with immunocytochemistry about the presence of this protease inhibitor in neoplastic thyroid tissue. Immunoprinting with the anti-alpha 1-antitrypsin antibody revealed an intense immunoreactive band of 53 kDa in the extracts prepared from tumoral tissue. This band had exactly the same apparent molecular mass previously described by others for alpha 1-antitrypsin purified from plasma and was identical to the molecular mass of the purified commercial standard employed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712295     DOI: 10.1097/00000478-199608000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

3.  Dynamic expression of the sodium-vitamin C co-transporters, SVCT1 and SVCT2, during perinatal kidney development.

Authors:  Francisco Nualart; Tamara Castro; Marcela Low; Juan Pablo Henríquez; Karina Oyarce; Pedro Cisternas; Andrea García; Alejandro J Yáñez; Romina Bertinat; Viviana P Montecinos; María Angeles García-Robles
Journal:  Histochem Cell Biol       Date:  2012-09-19       Impact factor: 4.304

4.  Bioinformatics analysis of prognostic value and immune cell infiltration of SERPINA1 gene in cutaneous melanoma.

Authors:  Fangjuan Hu; Ruqi Mei; Haiyan Zhang; Daijun Hao; Wei Li
Journal:  Ann Transl Med       Date:  2022-09

5.  Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation.

Authors:  Klemens Vierlinger; Markus H Mansfeld; Oskar Koperek; Christa Nöhammer; Klaus Kaserer; Friedrich Leisch
Journal:  BMC Med Genomics       Date:  2011-04-06       Impact factor: 3.063

6.  Alpha-1 Antitrypsin Blood Levels as Indicator for the Efficacy of Cancer Treatment.

Authors:  Zeyad J El-Akawi; Aymen M Abu-Awad; Nabil A Khouri
Journal:  World J Oncol       Date:  2013-05-06

7.  Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment.

Authors:  Afshan Masood; Hicham Benabdelkamel; Aishah A Ekhzaimy; Assim A Alfadda
Journal:  Molecules       Date:  2020-06-19       Impact factor: 4.411

8.  Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins.

Authors:  Mardiaty Iryani Abdullah; Ching Chin Lee; Sarni Mat Junit; Khoon Leong Ng; Onn Haji Hashim
Journal:  PeerJ       Date:  2016-09-13       Impact factor: 2.984

9.  A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.

Authors:  Marcio de Souza Cavalcante; José Camilo Torres-Romero; Marina Duarte Pinto Lobo; Frederico Bruno Mendes Batista Moreno; Leonardo Primo Bezerra; Diego Silva Lima; Jesamar Correia Matos; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Biomark Res       Date:  2016-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.